155.51
-1.23(-0.78%)
Currency In USD
| Previous Close | 156.74 |
| Open | 156.7 |
| Day High | 156.7 |
| Day Low | 151.83 |
| 52-Week High | 175.86 |
| 52-Week Low | 110.04 |
| Volume | 1.55M |
| Average Volume | 1.64M |
| Market Cap | 22.81B |
| PE | 14.19 |
| EPS | 10.96 |
| Moving Average 50 Days | 146.06 |
| Moving Average 200 Days | 135.51 |
| Change | -1.23 |
If you invested $1000 in Biogen Inc. (BIIB) 10 years ago, it would be worth $523.22 as of November 10, 2025 at a share price of $155.51. Whereas If you bought $1000 worth of Biogen Inc. (BIIB) shares 5 years ago, it would be worth $657.99 as of November 10, 2025 at a share price of $155.51.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025
GlobeNewswire Inc.
Nov 03, 2025 12:30 PM GMT
Oral presentation to share first-of-its-kind longitudinal gene expression data in IgA nephropathy, unveiling novel insights into the mechanism of action of felzartamab and advancing the understanding of its disease modifying potentialExhibitor Spotli
Health Canada Grants Authorization for “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease
GlobeNewswire Inc.
Oct 26, 2025 11:30 PM GMT
In Canada, lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment or mild dementia due to Alzheimer’s disease (early AD) who are apolipoprotein E ε4 (ApoE ε4*) non-carriers or heterozygotes a
Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio
GlobeNewswire Inc.
Oct 24, 2025 11:30 AM GMT
The oral C5aR1 antagonist is designed to modulate neutrophil-driven inflammation, a central mechanism underlying many inflammatory diseases CAMBRIDGE, Mass. and CHICAGO, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Vanqua Bio t